about
Primary cutaneous lymphomas: diagnosis and treatmentCutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and managementPruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative ReviewMycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.Mycosis fungoides: case report and literature review.Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome.Follow-up of patients with mycosis fungoides after interferon α2b treatment failure.Novel therapeutic agents for cutaneous T-Cell lymphoma.Tissue and serum lipidome shows altered lipid composition with diagnostic potential in mycosis fungoidesCutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.Emerging treatment options for early mycosis fungoides.Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphomaUse of class I histone deacetylase inhibitor romidepsin in combination regimensDimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB.Pityriasis Lichenoides-like Mycosis Fungoides: Clinical and Histologic Features and Response to Phototherapy.Cutaneous T-cell lymphoma in sub-Saharan Africa.CD30-positive cutaneous lymphoma: report of four cases with an emphasis on clinicopathological correlationsEmerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.Genetic alterations in Sezary syndrome.Treatment algorithms for mature T-cell and natural killer-cell neoplasms.Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.The use of methotrexate in dermatology: a review.Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature.Emerging drugs for T-cell lymphoma.Institutional experience with a rotational total skin electron irradiation (RTSEI) technique-A three decade review (1981-2012).Mature T-cell leukemias: Molecular and Clinical Aspects.Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.Testicular manifestation of a transformed mycosis fungoides.Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma.Romidepsin for cutaneous T-cell lymphoma.Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma.Molecular detection of circulating Sezary cells in patients with mycosis fungoides: could it predict future development of secondary Sezary syndrome? A single-institution experience.Clinical application of lying-on-the-floor total skin electron irradiation for frail patients with cutaneous lymphoma: An emphasis on the importance of in vivo dosimetry.Interferon-based treatment for patients with mycosis fungoides and hepatitis C virus infection: a case series.Mycosis fungoides: therapeutic difficulties.COX-2 is a novel target in therapy of mycosis fungoides.Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
P2860
Q26772207-6D29B408-9310-4CDA-9957-9FD64E5562F0Q27024076-1A8B5437-EF37-4C1A-877D-AF13BD16A028Q28075343-5EF1B86E-1211-4C55-94C9-837252707890Q30252152-B0CCA136-ED58-4AB4-A408-C93A6FA6C7A5Q30276550-BFBED764-5C02-4381-9ECA-68FEA8CF9078Q34122035-B26EA3E4-9C30-46DF-A7E8-42D3DA37A93FQ34156362-3697E8A9-AF7C-4B14-878D-9B00FED4E464Q34516083-CED3081B-0409-4E71-970D-DE61EABE2668Q35064852-3A5B56D9-5CA9-4A0E-9C4C-77FDAB7B4E6DQ35620524-3EA0B9F2-F595-4431-9046-4C3EC9DEF30AQ36161365-51A09C3B-6AE6-4658-9D22-9CF35551F011Q36408197-F05F9996-2EB0-41ED-AF82-228565727647Q36470196-3D2A828A-8D22-4B5D-84ED-E4349F2D4098Q36635567-5BC5C2F9-1700-49CE-8F43-BE1BA386D17AQ37046394-F9C8D57E-7394-48C8-AF2F-024EDA0A8EF5Q37107439-B68ED8F2-0CEC-4ABD-B741-8BCD60EA9FD5Q37262461-5500BBFE-0EBF-4B57-8D59-B20D231DCA21Q37339353-856F2A47-FCA1-4F5C-B6F6-6C87E394937AQ37398969-B6502F09-58CB-41B9-ACD8-0A6BD54546CCQ37644628-4B1DA7A2-3F2B-45AC-8B55-5F33CD3F8E4FQ37809875-589F63D2-0D45-4F7E-87F2-144A9FEBDCE2Q37842481-B8046113-03A8-4F61-9D41-AB885C7E0F2FQ37932546-1C536ED6-FB25-4452-891C-EE3804CF4FE4Q37944565-5D74A752-43BF-4E6A-89D3-FD98E773E8F0Q37981730-6E81059D-0B04-457C-8A42-6F700BD0B23EQ38120303-67007199-83EB-4F8B-9BC6-83289F198920Q38196943-F4979C88-1CAE-406D-A4DE-7078CF00E6B6Q38220829-8C68A6C6-8F3B-4B1D-867A-CD3B20EEB8EFQ38598546-6F73F51C-0E34-418A-9C6F-B6420161B6B9Q38602496-1D7FFF88-D447-4AD8-B7B2-2117877F2839Q38629000-56446340-BFCB-4E0C-8827-4B5C8B58DACAQ38944684-28B5AD5B-C20A-4F57-B575-A2C00E2324BFQ39303355-99AE6571-54B2-428E-B02E-1C6EA8067435Q39633115-3C99B644-5B4F-4BA0-B601-9E0741368DB9Q39691435-084286AC-C93B-4C35-9601-2478D78FCF16Q40990481-12E7622D-8276-4005-B506-5559481A5A79Q42210289-D1BC8E99-2850-4B5B-90AF-9BBC9AE931F4Q42665053-2B3C1A43-0B3C-42AC-A119-D3FD8CA3B74CQ42873280-0029484A-165E-4DAA-AFE6-5F511AFAFEBBQ43597205-164AA6AF-0201-4ED4-99CA-7F639BF847D1
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
How I treat mycosis fungoides and Sézary syndrome.
@ast
How I treat mycosis fungoides and Sézary syndrome.
@en
How I treat mycosis fungoides and Sézary syndrome.
@nl
type
label
How I treat mycosis fungoides and Sézary syndrome.
@ast
How I treat mycosis fungoides and Sézary syndrome.
@en
How I treat mycosis fungoides and Sézary syndrome.
@nl
prefLabel
How I treat mycosis fungoides and Sézary syndrome.
@ast
How I treat mycosis fungoides and Sézary syndrome.
@en
How I treat mycosis fungoides and Sézary syndrome.
@nl
P2093
P1433
P1476
How I treat mycosis fungoides and Sézary syndrome.
@en
P2093
H Miles Prince
Richard T Hoppe
Sean Whittaker
P304
P356
10.1182/BLOOD-2009-07-202895
P407
P577
2009-08-20T00:00:00Z